HUE061931T2 - Módszerek és készítmények természetes ölõsejtek számára - Google Patents

Módszerek és készítmények természetes ölõsejtek számára

Info

Publication number
HUE061931T2
HUE061931T2 HUE19175670A HUE19175670A HUE061931T2 HU E061931 T2 HUE061931 T2 HU E061931T2 HU E19175670 A HUE19175670 A HU E19175670A HU E19175670 A HUE19175670 A HU E19175670A HU E061931 T2 HUE061931 T2 HU E061931T2
Authority
HU
Hungary
Prior art keywords
compositions
methods
natural killer
killer cells
cells
Prior art date
Application number
HUE19175670A
Other languages
English (en)
Inventor
Alicja Copik
Vijay Reddy
Jeremiah Oyer
Original Assignee
Univ Of Central Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Central Florida filed Critical Univ Of Central Florida
Publication of HUE061931T2 publication Critical patent/HUE061931T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4613Natural-killer cells [NK or NK-T]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464499Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0646Natural killers cells [NK], NKT cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48Blood cells, e.g. leukemia or lymphoma
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/70Undefined extracts
    • C12N2500/80Undefined extracts from animals
    • C12N2500/84Undefined extracts from animals from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2315Interleukin-15 (IL-15)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2321Interleukin-21 (IL-21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/599Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HUE19175670A 2012-06-28 2013-06-28 Módszerek és készítmények természetes ölõsejtek számára HUE061931T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261665591P 2012-06-28 2012-06-28

Publications (1)

Publication Number Publication Date
HUE061931T2 true HUE061931T2 (hu) 2023-09-28

Family

ID=49783918

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19175670A HUE061931T2 (hu) 2012-06-28 2013-06-28 Módszerek és készítmények természetes ölõsejtek számára

Country Status (16)

Country Link
US (5) US9623082B2 (hu)
EP (3) EP3578201B1 (hu)
AU (3) AU2013282353B2 (hu)
CA (1) CA2877968A1 (hu)
DK (1) DK3578201T3 (hu)
ES (1) ES2943932T3 (hu)
FI (1) FI3578201T3 (hu)
HR (1) HRP20230424T1 (hu)
HU (1) HUE061931T2 (hu)
LT (1) LT3578201T (hu)
PL (1) PL3578201T3 (hu)
PT (1) PT3578201T (hu)
RS (1) RS64172B1 (hu)
SG (2) SG11201408697QA (hu)
SI (1) SI3578201T1 (hu)
WO (1) WO2014005072A1 (hu)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
ES2612918T3 (es) * 2013-07-10 2017-05-19 Miltenyi Biotec Gmbh Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
IL294395A (en) * 2014-10-27 2022-08-01 Univ Central Florida Res Found Inc Methods and compositions for natural killer cells
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
SG11201903032SA (en) * 2016-10-05 2019-05-30 University Of Central Florida Research Foundation Inc Methods and compositions related to nk cell and anti-pdl1 cancer therapies
US10300089B2 (en) * 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
CA3056439A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CA3064897A1 (en) * 2017-05-25 2018-11-29 University Of Central Florida Research Foundation, Inc. Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
CN111757745B (zh) 2018-02-01 2022-11-04 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
WO2019165097A1 (en) * 2018-02-21 2019-08-29 Board Of Regents,The University Of Taxas System Universal antigen presenting cells and uses thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN109627342B (zh) * 2018-12-10 2022-12-06 苏州近岸蛋白质科技股份有限公司 应用于nk细胞培养的蛋白质、培养基配方组合及制备方法
US20220056092A1 (en) 2018-12-11 2022-02-24 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
KR20210132660A (ko) * 2019-01-24 2021-11-04 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 천연 살해 세포를 자극하기 위한 조성물 및 방법
CN113646008A (zh) * 2019-01-28 2021-11-12 罗德岛大学理事会 pHLIP®肽介导的细胞表面的表位束缚
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CA3132840A1 (en) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
US20220267398A1 (en) 2019-06-12 2022-08-25 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
AU2020290522A1 (en) 2019-06-12 2022-01-20 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
KR20220026575A (ko) * 2019-06-25 2022-03-04 시티 오브 호프 Pdl1 양성 nk 세포 암 치료
CN112391349B (zh) * 2019-08-19 2023-05-23 刘韬 滋养层细胞株及其制备方法和体外诱导扩增nk细胞的方法
WO2021040736A1 (en) 2019-08-30 2021-03-04 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
WO2021093881A1 (zh) * 2019-11-14 2021-05-20 上海鑫湾生物科技有限公司 用于调控酸性环境免疫应答的组合物、其制备方法和用途
WO2021116913A1 (en) * 2019-12-09 2021-06-17 Nantkwest, Inc. Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection
MX2022008415A (es) 2020-01-08 2022-08-08 Obsidian Therapeutics Inc Composiciones y metodos para la regulacion ajustable de la transcripcion.
WO2021188974A1 (en) * 2020-03-20 2021-09-23 Orgenesis Inc. Ribonucleases for treating viral infections
WO2021201679A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting coronaviruses
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
US20230203443A1 (en) * 2020-06-09 2023-06-29 Samsung Life Public Welfare Foundation Genetically manipulated cell strain for activating and amplifying nk cells and use thereof
US20240141295A1 (en) 2020-08-31 2024-05-02 City Of Hope Novel cell lines, methods of producing natural killer cells and uses thereof
WO2022150392A1 (en) 2021-01-05 2022-07-14 City Of Hope Natural killer cells engineered to reduce or eliminate cbl-b and uses thereof
KR20240036997A (ko) * 2022-09-14 2024-03-21 재단법인 한국마이크로의료로봇연구원 사이토카인 활성 강화된 자연살해세포 유래 엑소좀의 암 치료용 생물학적 조성물 및 이의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
KR100922809B1 (ko) * 1999-05-06 2009-10-21 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
EP1349873B1 (en) * 2000-09-14 2009-04-01 Beth Israel Deaconess Medical Center, Inc. Modulation of il-2- and il-15-mediated t cell responses
CA2446739A1 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US20030148454A1 (en) * 2001-11-02 2003-08-07 Trustees Of Boston University Virus-free vesicles for delivery of functional membrane bound proteins
WO2004098529A2 (en) * 2003-04-30 2004-11-18 Emory University Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
CN1893925B (zh) * 2003-08-21 2011-04-27 利普泰克有限公司 树突细胞的体内靶向
EP2641611A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2005070120A2 (en) 2004-01-09 2005-08-04 Serologicals Investment Company, Inc. Cell culture media
US7592313B2 (en) * 2004-05-17 2009-09-22 Board Of Trustees Of The University Of Illinois Method of stimulating proliferation of regulatory T cells in a diabetic mammal
JP5525689B2 (ja) 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
CA2504279A1 (en) * 2005-04-15 2006-10-15 University Of Saskatchewan Materials and method of modulating the immune response using t helper-antigen presenting cells
DK1963369T3 (da) * 2005-11-28 2013-06-03 Zymogenetics Inc Il-21-antagonister
MX2008007292A (es) * 2005-12-08 2008-10-17 Univ Louisville Res Found Composiciones inmunoestimuladoras y metodos.
CN101945893B (zh) * 2007-12-14 2015-02-25 诺沃-诺迪斯克有限公司 抗人nkg2d抗体及其用途
WO2010071836A1 (en) * 2008-12-19 2010-06-24 Inserm Il-15 mediated nk and t cell maturation
AR083044A1 (es) * 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
WO2012177788A1 (en) * 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
WO2013177187A2 (en) * 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
WO2013175237A1 (en) 2012-05-24 2013-11-28 Ucl Business Plc Composition comprising a cd2 ligation agent and a nkg2d ligation agent

Also Published As

Publication number Publication date
EP2866834B1 (en) 2019-05-22
RS64172B1 (sr) 2023-05-31
AU2019200525A1 (en) 2019-02-14
WO2014005072A1 (en) 2014-01-03
US20230321191A1 (en) 2023-10-12
AU2019200525B2 (en) 2021-01-21
US20150190471A1 (en) 2015-07-09
US9623082B2 (en) 2017-04-18
US11617781B2 (en) 2023-04-04
FI3578201T3 (fi) 2023-05-05
HRP20230424T1 (hr) 2023-07-07
PL3578201T3 (pl) 2023-09-11
PT3578201T (pt) 2023-05-10
EP3578201B1 (en) 2023-04-19
SG10201610915XA (en) 2017-02-27
DK3578201T3 (da) 2023-05-08
US20170319659A1 (en) 2017-11-09
SG11201408697QA (en) 2015-02-27
US10874715B2 (en) 2020-12-29
AU2021202439A1 (en) 2021-05-13
US10463715B2 (en) 2019-11-05
EP3578201A1 (en) 2019-12-11
SI3578201T1 (sl) 2023-06-30
EP4279579A3 (en) 2024-02-21
LT3578201T (lt) 2023-05-25
AU2013282353B2 (en) 2018-10-25
EP2866834A1 (en) 2015-05-06
EP2866834A4 (en) 2015-12-09
US20200138908A1 (en) 2020-05-07
CA2877968A1 (en) 2014-01-03
AU2013282353A1 (en) 2015-02-12
ES2943932T3 (es) 2023-06-16
EP4279579A2 (en) 2023-11-22
US20190117736A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
IL272539B (en) Preparations and methods for immunotherapy
SG10201610915XA (en) Methods and compositions for natural killer cells
HK1211620A1 (en) Natural killer cells and uses thereof
SG10201705024PA (en) Methods and compositions for separating or enriching cells
EP2836212A4 (en) NOVEL COMPOSITIONS AND METHOD
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
IL230237B (en) Fat Cell Compounds and Methods
EP2680837A4 (en) COMPOSITIONS AND METHODS COMPRISING C16: 1N7-PALMITOLATE
GB201200458D0 (en) Methods of preparing cells and compositions
IL227529A0 (en) Compounds and methods of cell transplantation
HK1205185A1 (en) Methods and composition related to brown adipose-like cells
EP2854530A4 (en) COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY
HK1206970A1 (en) Antigenic compositions and methods
IL229176A0 (en) Preparations of living cells and their uses
IL250307A0 (en) Pesticide preparations and methods
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
EP2766357A4 (en) MESOBILIVERDINE COMPOSITIONS AND METHOD THEREFOR
IL239529B (en) Preparations and methods for creating improved and different cells and organisms
HK1231520A1 (zh) 改進的基質穩定性組合物和方法
HK1210436A1 (en) Novel cell compositions and methods
GB201116340D0 (en) Compositions and methods